BionicM raises $4.5M Series B first close for powered prosthetics push
What's the deal? Japanese startup BionicM has raised US$5.46M in a first close of its Series B round. B Dash VenturesDealroom has a profile for this one. Try Dealroom → and Mitsubishi UFJ CapitalDealroom has a profile for this one. Try Dealroom → led the financing, alongside overseas and individual investors.
What does BionicM do? Spun out of the University of Tokyo, the company builds powered prosthetic legs that apply humanoid robotics to assist movement. Its flagship Bio Leg carries US FDA Class II registration and insurance reimbursement approval.
What's the endgame? The money will fund production, marketing, and sales for ASISTA, a new knee prosthetic slated for a 2027 US launch. BionicM describes it as the first electromechanical microprocessor knee to assist both flexion and extension.
Why now? In April 2025, the US introduced a dedicated billing code (L5827) for electromechanical prosthetic knees, with Bio Leg listed as an eligible product. That eases insurance claims, though existing eligibility criteria remain strict.
Including equity and grants, BionicM says its total raised stands at US$19.8M. Only three companies worldwide have commercialised powered prosthetics, chief executive officer Sun Xiaojun said, and most amputees still use conventional devices.
What could go wrong? The new billing code alone will not greatly widen access or coverage. BionicM also faces competition from ÖssurDealroom has a profile for this one. Try Dealroom →'s Power Knee and established makers of conventional microprocessor knees.
The signal: Prosthetics are shifting from passive support to active assistance as the US patient base ages. BionicM's round is modest, but it bets that Japanese robotics can crack a market the company estimates at US$769.2M.
Read more: prtimes.jp
Image credit: Generated with Gemini
